

Global Acute Myocardial Infarction Market Outlook 2025-2034: Growth Drivers, Share, And Trends

Acute Myocardial Infarction Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, May 26, 2025

/EINPresswire.com/ -- The Business Research Company's Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034

The Business
Research Company

The Business Research Company

The [acute myocardial infarction market](#), presenting strong growth in recent years, is anticipated to expand from \$1.47 billion in 2024 to \$1.56 billion in 2025, reflecting a compound annual

growth rate CAGR of 6.2%. The significant growth during this period can be attributed to smoking-related heart diseases, increasing hypertensive cases, enhanced emergency medical services, increasing awareness of heart disease risk factors, and early adoption of aspirin in cardiovascular care. But what does the future look like for this sector?

“

The Business Research Company's Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034”

The Business research company

Where Is The Acute Myocardial Infarction Market Headed In The Future?

Projecting ahead, the acute myocardial infarction market is expected to witness robust growth, surging to \$1.97 billion in 2029 at a CAGR of 6.0%. This future growth is expected to be fueled by the rising demand for minimally invasive cardiac procedures, increasing investments in heart repair through regenerative medicine, increasing obesity and diabetes cases, and a growing focus on personalized medicine for heart disease. During this forecast period, major trends are anticipated to include artificial intelligence AI-driven early detection systems, wearable ECG monitoring devices, the advent of nanotechnology in drug delivery, three-dimensional 3D bioprinting of cardiac tissues, and advanced robotic-assisted cardiac surgeries.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=23291&type=smp>

what's driving this growth of acute myocardial infarction market?

The increasing incidence of hypertension is anticipated to propel the acute myocardial infarction market forward. Hypertension, characterized by persistently high blood pressure, significantly increases the risk of heart diseases, stroke, and other health complications. The risk is exacerbated by inactive lifestyles resulting from desk jobs, excessive screen time, and minimal exercise. These factors contribute to acute myocardial infarction by damaging arteries, helping plaque buildup, and increasing the risk of blood clots, which can block coronary arteries. In fact, a report published by the Australian Bureau of Statistics in October 2024 highlighted that hypertension prevalence had reached 11.6% 3.0 million people in 2022. Consequently, the rising cases of hypertension are driving the growth of the acute myocardial infarction market.

Who Are The Key Players In The Acute Myocardial Infarction Market?

Notable Industry players operating within the acute myocardial infarction market include Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Siemens Healthineers, Fujifilm Holdings Corporation, Koninklijke Philips N.V., Boston Scientific Corporation, Daiichi Sankyo Company Limited, Terumo Corporation, MicroPort Scientific Corporation, Ionis Pharmaceuticals Inc., CellProthera, Athersys Inc., BioCardia Inc., and Serca Pharmaceuticals.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/acute-myocardial-infarction-global-market-report>

What's The Latest Trend In The Acute Myocardial Infarction Market?

Interestingly, these major companies operating in the acute myocardial infarction market are focusing on obtaining regulatory approvals to expand their product portfolio, enhance treatment efficacy, and strengthen their market position. For instance, in March 2025, SunGen Biomedical received FDA Fast Track Designation for its monoclonal antibody drug, SGC001, the world's first developed for emergency treatment of acute myocardial infarction AMI. Such advancements offer significant promise towards better handling of acute myocardial infarction cases world over.

How Is The [Acute Myocardial Infarction Market Segmented](#)?

The acute myocardial infarction market report defines the market across various segments -1 By Type: ST-Elevation Myocardial Infarction STEMI, Non-ST-Elevation Myocardial Infarction NSTEMI
2 By Treatment Type: Thrombolytic Therapy, Percutaneous Coronary Intervention PCI, Coronary

Artery Bypass Grafting CABG, Medications

3 By Diagnosis Method: Electrocardiogram, Cardiac Biomarkers, Echocardiography, Coronary Angiography, Magnetic Resonance Imaging MRI, Computed Tomography CT Scan

4 By Route Of Administration: Oral Route, Intravenous IV Route, Subcutaneous Route, Transdermal Route, Sublingual Route

5 By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Specialty Cardiac Centers, Research Institutes

What Are The Regional Insights Of The Acute Myocardial Infarction Market?

On the geographic front, North America was the largest region in the acute myocardial infarction market in 2024, with Asia-Pacific expected to see the fastest growth during the forecast period. The report covers various regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse For More Similar Reports-

Acute Myeloid Leukemia Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report>

Acute Ischemic Stroke Drugs Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-drugs-global-market-report>

Acute Pancreatitis Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report>

Becoming familiar with the industry is crucial. The Business Research Company, with a portfolio of over 15000+ reports across 27 industries spanning 60+ geographies, has a solid reputation for providing comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, in-depth secondary research, and unique perspectives from industry leaders, you can get the information you need to maintain an edge.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/816125972>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.